Please assess the completion status of the following clinical trial:

Trial Title: Progesterone in Threatened Abortion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women attending the emergency room of the study sites with the following characteristics:~* Able and willing to sign the Subject Informed Consent Form and adhere to the study visit schedule;~* Age: 18-37 years;~* BMI: 18-28 kg/m2;~* Symptoms of threatened abortion (vaginal bleeding , with or without pelvic pain);~* Ultrasound proof of viable singleton intrauterine pregnancy (positive foetal heart beat);~* Gestation week ≥6 weeks (5 w +1d) and \<12 weeks (11 w + 1d) according to ultrasound dating (CRL);~* Closed uterine cervix;~* At the first case of threatened abortion in the current pregnancy.~Exclusion Criteria:~* Pregnancy obtained via ART treatment;~* Subchorionic haematoma with \>50% placental detachment;~* History of recurrent miscarriage;~* Severe uterine malformations;~* Known hypersensitivity to study medication;~* Neoplasias (known or suspected breast or genital tract cancer);~* Severe impairment of hepatic or renal function;~* Use of concomitant medications that might interfere with study evaluations (other hormonal treatment or drugs affecting uterine contractility);~* Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events;~* Porphyria;~* A history of idiopathic jaundice, severe pruritus or pemphigoid gestationis during pregnancy;~* Antiphospholipid syndrome;~* Diabetes mellitus;~* Known thyroid diseases or autoimmune conditions.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- Progesterone (Type: EXPERIMENTAL): 25 mg of subcutaneous progesterone will be administered twice à day until the 12th week of gestation.
- Placebo (Type: PLACEBO_COMPARATOR): placebo will be administered twice à day until the 12th week of gestation.

Based on this trial design, predict the completion outcome and termination type (if applicable).